Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Investing.com -- Morgan Stanley slashed its price target on Moderna Inc (BMV ... ongoing competitive pressures in the vaccine market. The firm noted Moderna's reduced 2024 sales forecast of ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving ...

Investing.com -- Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research report report published on Monday,Benzinga reports. Evercore ISI currently has ...

Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to ... success for the company’s EBV vaccine from 85% to 70%. The firm’s 12-month price target is based on a 100% discounted ...

Moderna's (MRNA) price target slashed to $38 from $70 by Morgan ... Analysts cite lowered 2025 revenue outlook and vaccine market competition. Fintech leaders SoFi (SOFI) and Affirm (AFRM) have ...